High expression of YTHDF3 (HR: 1.025, 95% CI: 1.009–1.042), ZC3H13 (HR: 1.039, 95% CI: 1.006–1.074), LRPPRC (HR: 1.016, 95% CI: 1.001–1.031) and METTL16 (HR: 1.101, 95% CI: 1.003–1.207) indicated poor survival in patients with breast cancer, while high expression of RBM15B (HR: 0.931, 95% CI: 0.888–0.977) corresponds with better survival (Figure 4A). Here, RBM15B is linked to breast carcinoma.